News & Events
-
April 25, 2017
Second Annual Workshop On Clinical Outcome Assessments In Cancer Clinical Trials
Assessing Tolerability of Cancer Treatments: Optimizing the Role of Patient-Reported Data April 25, 2017 Hyatt Regency Bethesda 1 Bethesda Metro Center Bethesda, MD 20814 CO-SPONSORED BY: Critical Path Institute U.S. Food and Drug Administration Workshop Agenda 7:30-8:15 am Registration and Continental Breakfast – Regency I and II 8:15-8:30 am Welcome and Opening RemarksPaul G. Kluetz,...... -
April 5, 2017
INC Necrotizing Enterocolitis (NEC) Workgroup Meeting at UC Davis
On behalf of the NEC Co-Chairs, Mickey Caplan and Jennifer Canvasser, thank you for contributing to the success of the International Neonatal Consortium’s NEC Workgroup meeting at UC – Davis on April 5, 2017. For your information, the meeting slides can be found here. Mickey Caplan’s brief meeting overview follows: Thanks to you all for participating in...... -
March 27, 2017 - March 29, 2017
Applying Regulatory Science to Neonates: Third Annual Scientific Workshop
March 27 – 29, 2017 Bethesda North Marriott Hotel and Conference Center 5701 Marinelli Road, North Bethesda, Maryland 20852 USA Sponsors: Critical Path Institute and U.S. Food and Drug Administration Agenda – Day 1, March 27, 2017 8:00 am – 4:00 pm (Brookside B) INC Severity Scale for Neonatal Adverse Events Workgroup Meeting 8:00 am – 4:30...... -
March 20, 2017 - March 23, 2017
2017 CPTR Workshop
Diverse group of TB stakeholders share and learn about new developments in TB drug and drug susceptibility testing research </div The 8th Annual CPTR Initiative Workshop drew more than 150 participants to Washington, D.C. to learn and share information critical to the rapid advancement of new TB combination therapies, drug susceptibility tests (DST), and the...... -
March 10, 2017
Mobile Devices in Clinical Trials for Neurological Diseases: CDISC Standards Development
March 10, 2017 Pointe Hilton Tapatio Cliffs Resort | Phoenix, AZ Overview and Objectives The Coalition Against Major Diseases (CAMD), a consortium within the Critical Path Institute, is focused on accelerating the regulatory sciences required to advance innovative treatments for Alzheimer Disease and related neurodegenerative diseases with impaired cognition and function. In collaboration with......